Evidence map›Paper›PMID 19735442›Full record

ArticleMolecular microbiology2009

Contribution of AmyA, an extracellular alpha-glucan degrading enzyme, to group A streptococcal host-pathogen interaction.

Samuel A Shelburne Iii, David B Keith, Michael T Davenport, Stephen B Beres, Ronan K Carroll, James M Musser

Open access · bronzeAbstract read
In one paragraph

Article in Molecular microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Expanding the genetic toolbox for the obligate human pathogenFrontiers in bioengineering and biotechnology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Samuel A Shelburne IiiDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
David B KeithDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
Michael T DavenportDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
Stephen B BeresDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
Ronan K CarrollDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
James M MusserDepartment of Infectious Diseases, MD Anderson Cancer Center, Houston, TX 77030, USA.Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Analysis Of Group A Streptococcus-Saliva InteractionK08AI064564 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2006 to 2009
$492k
NIAID NIH HHS AI-064564NIAID NIH HHS K08 AI064564
6 · The paper itself

Abstract

alpha-Glucans such as starch and glycogen are abundant in the human oropharynx, the main site of group A Streptococcus (GAS) infection. However, the role in pathogenesis of GAS extracellular alpha-glucan binding and degrading enzymes is unknown. The serotype M1 GAS genome encodes two extracellular proteins putatively involved in alpha-glucan binding and degradation; pulA encodes a cell wall anchored pullulanase and amyA encodes a freely secreted putative cyclomaltodextrin alpha-glucanotransferase. Genetic inactivation of amyA, but not pulA, abolished GAS alpha-glucan degradation. The DeltaamyA strain had a slower rate of translocation across human pharyngeal epithelial cells. Consistent with this finding, the DeltaamyA strain was less virulent following mouse mucosal challenge. Recombinant AmyA degraded alpha-glucans into beta-cyclomaltodextrins that reduced pharyngeal cell transepithelial resistance, providing a physiologic explanation for the observed transepithelial migration phenotype. Higher amyA transcript levels were present in serotype M1 GAS strains causing invasive infection compared with strains causing pharyngitis. GAS proliferation in a defined alpha-glucan-containing medium was dependent on the presence of human salivary alpha-amylase. These data delineate the molecular mechanisms by which alpha-glucan degradation contributes to GAS host-pathogen interaction, including how GAS uses human salivary alpha-amylase for its own metabolic benefit.

Indexed as

Host-Pathogen InteractionsAnimalsBacterial ProteinsCell LineCyclodextrinsFemaleGenetic Complementation TestGlucansGlucosyltransferasesHumansMiceMutagenesis, InsertionalMutationPharyngitisRNA, BacterialStreptococcal InfectionsBacterial ProteinsCyclodextrinscyclomaltodextrin glucanotransferaseGlucansGlucosyltransferasesRNA, Bacterial

Identifiers

PMID19735442
PMCPMC4557622
OpenAlexW2132907382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.